US Based Megna Health's Rapid COVID-19 Antibody Test Receives Point of Care Emergency Use Authorization

Megna Health announced today that its Rapid COVID-19 IgM/IgG Antibody Combo Test, previously authorized for use under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization, is now available for Point of Care Settings. The test can now be administered in CLIA-waived settings using fingerstick whole blood to detect COVID-19 antibodies. Read more.